Myeloperoxidase and Atherosclerosis

Current Cardiovascular Risk Reports

Volumn 7, Issue 2, 2013, Pages 102-107

  Kamanna, Vaijinath S ^a,b   Ganji, Shobha H ^a   Kashyap, Moti L ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Apolipoprotein AI; Atherosclerosis; Cardiovascular disease; Coronary artery disease; High density lipoproteins; Inflammation; Low density lipoproteins; Myeloperoxidase; Neutrophils; Niacin; Statins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOPEROXIDASE; NICOTINIC ACID; NITRIC OXIDE; PRAVASTATIN; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME RELEASE; HUMAN; NEUTROPHIL; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 84875469812     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-013-0291-3     Document Type: Review

References (63)

1. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med. 1980; 93: 480-9.
2. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis. 2010; 210: 1-13. A comprehensive review on the role of neutrophils in atherosclerosis.
3. Zheng R, Brennan ML, Fu X, et al. Association between myeloperoxidase and risk of coronary artery disease. JAMA. 2001; 286: 2136-42.
4. Brennan ML, Penn MS, van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Eng J Med. 2003; 349: 1595-604.
5. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003; 108: 1440-5.
6. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with future risk of coronary artery disease in apparently healthy individuals. J Am Coll Cardiol. 2007; 50: 159-65.
7. Tang WH, Katz R, Brennan ML, et al. Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol. 2009; 103: 1269-74. This is a case-control study showing serum MPO levels are associated with the risk of future development of coronary artery disease in healthy subjects.
8. Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. J Am Coll Cardiol Img. 2009; 2: 1093-9.
9. Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma levels of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007; 49: 1993-2000.
10. Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med. 2012; 271: 43-50.
11. Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation. 2010; 122: 2505-13.
12. Tavora FR, Ripple M, Li L, et al. Monocyte and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord. 2009; 9: 27-33.
13. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002; 106: 2894-900.
14. Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 2000; 104: 10-5.
15. Nikpoor B, Turecki G, Fournier C, et al. A functional myeloperoxidase polymorphic variant is associated with coronary artery diseasein French-Canadians. Am Heart J. 2001; 142: 336-9.
16. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. 2003; 84: 172-6.
17. Asselbergs FW, Tervaert JW, Tio RA, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Eng J Med. 2004; 350: 516-8.
18. Stefanescu A, Braun S, Ndrepepa G, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J. 2008; 155: 356-60.
19. Kubala L, Lu G, Baldus S, et al. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta. 2008; 394: 59-62.
20. Eggers KM, Dellborg M, Johnston N, et al. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem. 2010; 43: 240-5.
21. Brugger-Anderson T, Aarstoy H, Grundt H, et al. The long-term prognostic value of multiple biomarkers following a myocardial infarction. Thromb Res. 2008; 123: 60-6.
22. Weiss SJ. Tissue distruction by neutrophils. N Eng J Med. 1989; 320: 365-76.
23. Chen Y, Hashiguchi N, Yip L, et al. Hypertonic saline enhances neutrophil elastase release through activation of P2 and A3 receptors. Am J Physiol. 2006; 290: C1051-9.
24. Junger WG, Hyot DB, Davis RE, et al. Hypertonicity regulates the function of human neutrophils by modulating chemoattractant receptor signaling and activating mitogen-activated protein kinase p38. J Clin Invest. 1998; 101: 2768-79.
25. Mocsai A, Jakus Z, Vontus T, et al. Kinase pathways in chemoattractant-induced degranulation of neutrophils: role of p38 mitogen-activated protein kinase activated by Src family kinases. J Immunol. 2000; 164: 4321-31.
26. Yan SR, Berton G. Regulation of Src family tyrosine kinase activities in adherent human neutrophils. J Biol Chem. 1996; 271: 23464-71.
27. Brumell JH, Burkhardt AL, Bolen JB, et al. Endogenous reactive oxygen intermediates activate tyrosine kinases in human neutrophils. J Biol Chem. 1996; 271: 1455-61.
28. Daughetty A, Dunn JL, Rateri DL, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994; 94: 437-44.
29. Hazen SL, Gaut JP, Crowley JR, et al. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino acid derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions, and advanced atherosclerotic lesions. Biochem J. 2000; 352: 693-9.
30. Ross R. Atherosclerosis-an inflammatory disease. New Eng J Med. 1999; 340: 115-26.
31. Landmesser U, Hornig B, Drexler H. Endothelial function. A critical determinant in atherosclerosis. Circulation. 2004; 109(Suppl I): II-27-II-33.
32. Ignarro LJ, Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Diab Rep. 2005; 5: 17-23.
33. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000; 275: 37524-32.
34. Nicholls SJ, Hazen SL. Myeloperoxidase and Cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005; 25: 1102-11.
35. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002; 296: 2391-4.
36. Rudolph TK, Wipper S, Reiter B, et al. Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J. 2011; 33: 1625-34.
37. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004; 110: 1134-9.
38. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997; 272: 20963-6.
39. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoproteins, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979; 76: 333-7.
40. Hazen SL, Heinecke JW. 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997; 99: 2075-81.
41. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999; 103: 1547-60.
42. Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000; 105: 1095-108.
43. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia, and atherogenesis. Nat Med. 2007; 13: 1176-84.
44. Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med. 2007; 4: 102-9.
45. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003; 108: 2751-6.
46. Panzenboeck U, Raitmayer S, Reicher H, et al. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem. 1997; 272: 29711-20.
47. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABAA1-dependent cholesterol transport. Proc Natl Acad Sci USA. 2004; 101: 13032-7.
48. Pennathur S, Bergt C, Shao B, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem. 2004; 27: 42977-83.
49. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004; 114: 529-41.
50. Undurti A, Huang Y, Lupica JA, et al. Modification of HDL by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem. 2009; 284: 30825-35.
51. Shao B, Oda MN, Oram JF, et al. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol. 2006; 21: 322-8.
52. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res. 2009; 50: S346-51.
53. Smith JD. Myeloperoxidase, inflammation, and dysfunctional HDL. J Clin Lipidol. 2010; 4: 382-8.
54. Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004; 24: 1309-14.
55. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol. 2004; 24: 1143-6.
56. Malle E, Furtmuller PG, Sattler W, et al. Myeloperoxidase: a target for drug development? Brit J Pharmacol. 2007; 1-17.
57. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun. 2005; 331: 442-51.
58. Zhou T, Shou SH, Qi SS, et al. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta. 2006; 368: 168-72.
59. Andreou I, Tousoulis D, Miliou A, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure. A randomized placebo-controlled study. Atherosclerosis. 2010; 210: 194-8.
60. Ganji SH, Xiong X, Kamanna VS, Kashyap ML. Niacin inhibits myeloperoxidase activity and oxidative degradation of HDL and apoAI in human leukocytic myeloid cell line HL-60: Impact on anti-infalmmatory properties of HDL. Atherosclerosis. 2009; 10(2): e182.
61. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009; 202: 68-75.
62. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008; 101: 20B-6.
63. Wu BJ, Yan L, Charlton F, et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010; 30: 968-75.